# Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

> **NCT03331289** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 107 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** Exenatide
- **DRUG:** Dapagliflozin
- **DRUG:** Exenatide and Dapagliflozin

## Key facts

- **NCT ID:** NCT03331289
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-11-04
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331289, "Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03331289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*